News >

Longer Follow-Up Shows Survival Increase With Rocapuldencel-T in mRCC

Published: Tuesday, Sep 26, 2017

Robert A. Figlin, MD, FACP

Robert A. Figlin, MD, FACP
Patients with metastatic renal cell carcinoma (RCC) appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells, according to updated results from the phase III randomized ADAPT trial presented at the 2017 ESMO Congress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication